BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Friedman SL, Pinzani M. Hepatic fibrosis 2022: Unmet needs and a blueprint for the future. Hepatology 2022;75:473-88. [PMID: 34923653 DOI: 10.1002/hep.32285] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 26.0] [Reference Citation Analysis]
Number Citing Articles
1 Lu H, Zheng C, Xiong B, Xia X. Efficacy and safety of heparin plus dexamethasone after partial splenic embolization for liver cirrhosis with massive splenomegaly. BMC Gastroenterol 2022;22:470. [DOI: 10.1186/s12876-022-02580-8] [Reference Citation Analysis]
2 Wang C, Chen T, Mu Y, Liang X, Xiong K, Ai L, Gu Y, Fan X, Liang H. FDRdb: a manually curated database of fibrotic disease–associated RNAome and high-throughput datasets. Database 2022;2022. [DOI: 10.1093/database/baac095] [Reference Citation Analysis]
3 Luo N, Zhong W, Li J, Zhai Z, Lu J, Dong R. Targeted activation of HNF4α/HGF1/FOXA2 reverses hepatic fibrosis via exosome-mediated delivery of CRISPR/dCas9-SAM system. Nanomedicine 2022. [DOI: 10.2217/nnm-2022-0083] [Reference Citation Analysis]
4 Zhao R, Zhao H, Guo Q, Mu Y, Zhang J, Su Y, Han Q. Edaravone protects against liver fibrosis progression via decreasing the IL-1β secretion of macrophages. Chemico-Biological Interactions 2022. [DOI: 10.1016/j.cbi.2022.110251] [Reference Citation Analysis]
5 Lonardo A, Mantovani A, Targher G, Baffy G. Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: Epidemiology, Pathogenesis, and Clinical and Research Implications. IJMS 2022;23:13320. [DOI: 10.3390/ijms232113320] [Reference Citation Analysis]
6 Wang L, Feng J, Deng Y, Yang Q, Wei Q, Ye D, Rong X, Guo J. CCAAT/Enhancer-Binding Proteins in Fibrosis: Complex Roles Beyond Conventional Understanding. Research 2022;2022:1-42. [DOI: 10.34133/2022/9891689] [Reference Citation Analysis]
7 Wu ZC, Liu XY, Liu JY, Piao JS, Piao MG. Preparation of Betulinic Acid Galactosylated Chitosan Nanoparticles and Their Effect on Liver Fibrosis. Int J Nanomedicine 2022;17:4195-210. [PMID: 36134203 DOI: 10.2147/IJN.S373430] [Reference Citation Analysis]
8 Sun X, Ni HB, Xue J, Wang S, Aljbri A, Wang L, Ren TH, Li X, Niu M. Bibliometric-analysis visualization and review of non-invasive methods for monitoring and managing the portal hypertension. Front Med 2022;9. [DOI: 10.3389/fmed.2022.960316] [Reference Citation Analysis]
9 Wang X. Challenges and opportunities in nonalcoholic steatohepatitis. Medical Review 2022;0. [DOI: 10.1515/mr-2022-0024] [Reference Citation Analysis]
10 Ren H, Li W, Liu X, Zhao N. γδ T cells: The potential role in liver disease and implications for cancer immunotherapy. J Leukoc Biol 2022. [PMID: 36098208 DOI: 10.1002/JLB.5MR0822-733RRR] [Reference Citation Analysis]
11 Anne van Os E, Cools L, Eysackers N, Szafranska K, Smout A, Verhulst S, Reynaert H, Mccourt P, Mannaerts I, van Grunsven LA. Modelling fatty liver disease with mouse liver-derived multicellular spheroids. Biomaterials 2022. [DOI: 10.1016/j.biomaterials.2022.121817] [Reference Citation Analysis]
12 Ariyachet C, Chuaypen N, Kaewsapsak P, Chantaravisoot N, Jindatip D, Potikanond S, Tangkijvanich P. MicroRNA-223 Suppresses Human Hepatic Stellate Cell Activation Partly via Regulating the Actin Cytoskeleton and Alleviates Fibrosis in Organoid Models of Liver Injury. Int J Mol Sci 2022;23:9380. [PMID: 36012644 DOI: 10.3390/ijms23169380] [Reference Citation Analysis]
13 Eeckhoute J. Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis: Molecular and Multicellular Control of Evolving Diseased States. Cells 2022;11:2551. [DOI: 10.3390/cells11162551] [Reference Citation Analysis]
14 Zhu T, Lu XT, Liu ZY, Zhu HL. Dietary linoleic acid and the ratio of unsaturated to saturated fatty acids are inversely associated with significant liver fibrosis risk: A nationwide survey. Front Nutr 2022;9:938645. [PMID: 35958259 DOI: 10.3389/fnut.2022.938645] [Reference Citation Analysis]
15 Luo N, Zhong W, Li J, Lu J, Dong R. CRISPR/dCas9 for hepatic fibrosis therapy: implications and challenges. Mol Biol Rep 2022. [PMID: 35960410 DOI: 10.1007/s11033-022-07713-6] [Reference Citation Analysis]
16 Weiskirchen R. Special Issue on “Cellular and Molecular Mechanisms Underlying the Pathogenesis of Hepatic Fibrosis II”. Cells 2022;11:2403. [DOI: 10.3390/cells11152403] [Reference Citation Analysis]
17 Parola M. Follistatin-like protein 1 and chronic liver disease progression: a novel pro-inflammatory and pro-fibrogenic mediator? Ann Transl Med 2022;10:841. [PMID: 36035001 DOI: 10.21037/atm-22-3561] [Reference Citation Analysis]
18 Amer MA, Othman AI, El-Missiry MA, Farag AA, Amer ME. Proanthocyanidins attenuated liver damage and suppressed fibrosis in CCl4-treated rats. Environ Sci Pollut Res Int 2022. [PMID: 35881285 DOI: 10.1007/s11356-022-22051-7] [Reference Citation Analysis]
19 Qian K, Lei X, Liu G, Fang Y, Xie C, Wu X, Liu Q, Liu G, Cao Z, Zhang J, Kuang T, Yan L, Fu J, Du H, Liu Z, Chu Y, Xu G, Yamamoto H, Mori M, Liang XM, Xu X, Sun Y. Transient Receptor Potential Vanilloid-1 (TRPV1) Alleviates Hepatic Fibrosis via TGF-β Signaling. Disease Markers 2022;2022:1-15. [DOI: 10.1155/2022/3100943] [Reference Citation Analysis]
20 Xin Y, Liu F, Li D, Zhu J. Viscoelasticity assessment for in vivo quantification of muscle contusion injury in rats using shear wave elastography. Ultrasound Med Biol 2022:S0301-5629(22)00416-1. [PMID: 35868906 DOI: 10.1016/j.ultrasmedbio.2022.05.026] [Reference Citation Analysis]
21 Dai Y, Zhao Z, Liu C. Treatment of Liver Fibrosis: A 20-Year Bibliometric and Knowledge-Map Analysis. Front Pharmacol 2022;13:942841. [DOI: 10.3389/fphar.2022.942841] [Reference Citation Analysis]
22 Chen X, Wang Y, Ji S, Sun X, Feng Q, Yu H, Liu C. Hepatoprotective Efficacy and Interventional Mechanism of Qijia Rougan Decoction in Liver Fibrosis. Front Pharmacol 2022;13:911250. [DOI: 10.3389/fphar.2022.911250] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Kimura K, Kanto T, Shimoda S, Harada K, Kimura M, Nishikawa K, Imamura J, Ogawa E, Saio M, Ikura Y, Okusaka T, Inoue K, Ishikawa T, Ieiri I, Kishimoto J, Todaka K, Kamisawa T. Safety, tolerability, and anti-fibrotic efficacy of the CBP/β-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study. EBioMedicine 2022;80:104069. [PMID: 35605429 DOI: 10.1016/j.ebiom.2022.104069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Yan J, Liu Q, Tang Q, Zhang J, Jing X, Xia Y, Xu Y, Li J, Li Y, He J. Mesencephalic astrocyte-derived neurotrophic factor alleviates non-alcoholic steatohepatitis induced by Western diet in mice. FASEB J 2022;36:e22349. [PMID: 35567505 DOI: 10.1096/fj.202101975R] [Reference Citation Analysis]
25 Zhang J, Liu Y, Chen H, Yuan Q, Wang J, Niu M, Hou L, Gu J, Zhang J. MyD88 in hepatic stellate cells enhances liver fibrosis via promoting macrophage M1 polarization. Cell Death Dis 2022;13:411. [PMID: 35484116 DOI: 10.1038/s41419-022-04802-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Vu Ngoc H, Thuy LTT, Hai H, Dat NQ, Hoang DV, Hanh NV, Phuong DM, Hoang TH, Sawai H, Shiro Y, Sato-matsubara M, Oikawa D, Tokunaga F, Yoshizato K, Kawada N. Capacity of extracellular globins to reduce liver fibrosis via scavenging reactive oxygen species and promoting MMP-1 secretion. Redox Biology 2022. [DOI: 10.1016/j.redox.2022.102286] [Reference Citation Analysis]
27 Sato T, Head KZ, Li J, Dolin CE, Wilkey D, Skirtich N, Mccreary DD, Liu S, Beier JI, Mcenaney RM, Merchant ML, Arteel GE. Fibrosis resolution in the mouse liver: role of Mmp12 and potential role of Calpain 1/2.. [DOI: 10.1101/2022.02.15.480540] [Reference Citation Analysis]
28 田 莉. Study on the Mechanism of Blood Circulation in Patients with Liver Fibrosis. ACM 2022;12:9816-9821. [DOI: 10.12677/acm.2022.12111416] [Reference Citation Analysis]